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Patients with high-grade, serous epithelial ovarian carcinoma (HGSOC) are generally diagnosed with extensive peritoneal
metastases, and exhibit 5-year survival rates <30%. A subset of these tumours, defined as "immunoreactive," overexpress
mRNA encoding the T-cell-recruiting chemokine CXCL10 (10-kDa interferon gamma-induced protein; C-X-C motif chemokine
10). Tumour-infiltrating CD4+CD8+ T-cells are a well-documented, positive prognostic indicator for HGSOC patients; paradoxi-
cally, however, patients diagnosed with HGSOC (overexpressing CXCL10 and therefore theorised to recruit T-cells) typicalty
exhibit poor survival. Recently, an "antagonistic" CXCL10 variant was identified that inhibited leucocyte recruitment to
inflamed liver in vivo (Casrouge et al., I CIin tnvest 2OLli721:308-17). We hypothesised that -immunoreactive" HGSOC might
also express antagonistic CXCL10, interfering with leucocyte recruitment and contributing to poor patient prognosis. CXCL10
expression was analysed in HGSOC tissues grouped according to pathology, grade and F|GO stage at diagnosis, and its local-
isation and association with T-cells estabtished by immunohistochemical staining in tissue microarrays. CXCL10 expression
was increased in a subset of serous epithetiat tumour samples; however, it did not correlate well with CD45-positive tumour
infiltrate. lmmunoprecipitation and de novo sequence analysis of CXCL10 identified the N-terminally cleaved, "antagonistic"
variant of CXCL10 specifically in malignant tumours, and not in benign ovarian disease, The data demonstrate the presence of
the antagonistic form of CXCLlO in HGSOC for the first time, and provide a partial explanation for reduced leucocyte infiltra-
tion observed in these tumours. We suggest that CXCL10 cleavage and subsequent antagonism of immune ceil recruitment
may be a feature of the "immunoreactive" HGSOC subtype, leading to early impairment of the immune response and subse-
quently worsening patient prognosis.
Epithelial ovarian cancers account for between 80 and 957o
of ovarian tumours diagnosed, and remain the fourth highest
cause of cancer-related mortality for women with an esti-
mated 
-22,000 new cases and -14,000 deaths in the United
States in 2010.r Despite a relatively low population incidence
Key words: CXCLI0, ovarian cancer, leucoqte, dipeptidyl peptidase,
mass sPectrometry
Additional Supporting Information may be found in the online
version of this article.
Conflict of interest Nothing to report.
*A.R and ).RR. contributed equally to this work.
Grant sponsorg: Ovarian Cancer Research Foundation
(www.OCRF.com.au), Victorian Government's Operational
lnfrastructure Support Program.
0Ol: 10. 1002/ijc.28393
History: Received l0 Feb 2013; Accepted 3 |uly 2013; Online 20 |ul
20t3
Conespondence to; Dr. Andrew N. Stephens, Prince Henry's
Institute of Medical Research, PO Box 5152, Clayton, VIC 3168,
Australia, Tel.: + 6 I 3-9594 -7 9 12, F ax: + 6 | 3 -9 59 4 -7 909,
E-mail: andrew.stephens@princehenrys.org
lnt. f. Cancer: 7t4,530-541 (2014) @ 2013 UICC
and incremental improvements in surgery and chemotherapy,
the S-year survival rate for patients diagnosed with ovarian
neoplasms has improved only marginally over time. Although
traditionally classified as serous, mucinous, clear cell or endo-
metroid based on their histological appearance, epithelial
ovarian tunrours are increasingly considered as different dis-
ease subtypes with characteristic molecular genetic alterations
(reviewed in Ref. 2). In particular, high- or low-grade serous
epithelial tumours are now believed to represent distinct
molecular diseases (termed Type I or Type lI) with different
underlying pathologies. Low-grade (Type I) tumours are
believed to progress through benign and borderline stages to
malignancy, typically exhibit mutations in KRAS and BRAF
(amongst others) and are generally diagnosed at an early
stage. By contrast, high-grade (T1pe II) serous tumours have
no well-defined driver point mutations, characteristically
overexpress TP53 and metastasise early in their progression.
Their aetiology is also unclear, with several hypotheses
regarding the location of origin and precursor cell types
involved.r
The importance of the host immune response in the
development and progression of ovarian tumours has now
been firmly established; indeed, as for other cancer types the
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What's new?
The development and progression of ovarian cancer is influenced by tumor-infiltrating immune celts, particularly
T-lymphocyte-recruiting chemokines. The chemokine cxcL10 may piay a rey role in tiis anti-tumor ir*unu ,.rponse, und
ther:ly aid survivat, though previous studies have been inconclusive. Here, an antagonistic form of CXCL10, recentty reported
to inhibit leukocyte recruitment in liver disease, was isolated from malignant, high-grade serous epithelial ovarian carcinomas(HGsoCs) but not from benign HGSoC. The presence of the antagonistic form correlated with decreased leukocyte infiltration
into tumors, suggesting a novel mechanism by which tumors might attenuate the anti-tumor immune response.
presence and type of tumour-infiltrating lymphocytes in
ovarian tumours is directly correlated with prognosis.4-., In
this context, clremokines play a rnajor role via the recruit_
ment of activated T-lymphocytes and promotion of a Thl_
type immune response. The chemokine CXCLI0 (10-kDa
interferon gamma-induced protein; C-X_C motif chemokine
l0) is one of three CXC-type chemokines (CXCI_9 or MIG:
CXCLIO or lPl0 and CXCLII or I'I'AC) that bind and signal
via their G-coupled protein receptor CXCR3. Expressetl in
diverse cell types, CXCLf0 is a potent chemoattractant that
recruits activated CD4+ and CDg+ lymphocytes, NK and
NKI' cells into sites of inflammation (reviewed in Ref. 7).
CXCLI0 also displays antiproliferative effects on endothelial
cells in vitro, and angiostatic and antitumour effect.s in vivo,
and is active against epithelial cells, fibroblasts and other cell
and tissue types.T These antiproliferative effects may be medi_
ated independently of the main CXCR3 receptor isoform(CXCR3-A) via binding to cell-surface glycosaminoglycanss
or possibly through one of two other known CXCR3 receDtor
isoforms (CXCR3-B).'g
Post-translational processing is an important regulator of
CXCLI0 function. In particular, the cleavage of a Val-pro
dipeptide from the N-terminus of CXCLiO, catalysed bv
dipeptidyl peptidases (Dppase) Dpp4, Dpp8 or Dppg,ro con_
verts it into a powerful antagonist of chemotaxis that retains
affinity for the CXCR3 receptor but fails to induce internalisa-
tion or receptor-mediated signalling.lt,t2 .Ihe importance ofthis modification in viuo was recently demonstrate<i by
Casrouge et al,1t who identified an increasetl abundance of
antagonistic, cleaved CXCLI0 in circulation in a cohort of
patients infected with hepatitis C virus. .fhese patients clis_
played impaired recruitment of circulating rno'onucrear cels
to the liver, leading to the failure of immune response ancl an
inability to clear the infection after treatment.il Thrs in siru
generation of antagonistic CXCLI0 helped to explain a long_
established negative correlation between elevated CXCLI0 lev-
els and poor response to therapy in these patients.
Several lines of evidence have suggested key roles forCXCLI0 in the pathogenesis of ovarian tumours. Cell lines
derived from epithelial ovarian tumours secrete CXCLIO
when stimulated with proinflammatory signals including vas_
cular endothelial growth factor (VEGF), prolactin, interferon
gamma (IFN1) or activated NF_rB, all of which have been
implicated in ovarian tumour progression.T Accordingly, thein vivo secretion of CXCLI0 and subsequent recruitment of
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activated TJymphocytes into tumour tissue have been associ-
ated with improved clinical outcome-,-t However, other stud-
ies have suggested that increased expression of CXCLIO does
not promote effective tumour suppression, but leads to
enhanced lymph node metastasis.14-r6 Decreased plasma
CXCLI0 levels in ovarian cancer patients have a.lso been pos_
itively correlated with progression-free ancl overall survival.rT
Although CXCLI0 clearly plays an important role in the pro_
gression and pathogenesis of ovarian cancers, the relationship
between its expression and tumour progression remains
undetermined.
The conflict between CXCLI0 expression and patient
prognosis prompted us to investigate whether cleavage of
CXCL1O rnight occur in ovarian tumours. In this pilot siudy,
we report on the expression of CXCLlO in a cohort of
women diagnosed with serous epithelial ovarian rurnours,
using a combination of tissue expression, irnrnunoassay and
irnrnunohistochemical analyses. Immunoprecipitation and
mass spectrometry were subsequently used to sequence the
N-terminus of CXCLI0 and establish the presence of cleaved
CXCLI0 in ovarian tumours.
filaterial and llethods
Ctinical samples
Protein and mRNA expression studies were carrie<i out using
matched sarnples of tissue, EDTA_chelated plasma and urine,
accessed from bio-banked samples collected prospectively
from women undergoing surgery for suspected gynaecological
malignancies during the period 2007_2010. All samples were
obtained frorn anaesthetised patients who had undergone noprior surgical treatment or neoadjuvant chemotherapy for
their tumours. All relevant clinical information, including a
thorough histological assessment of tumour tFpe, stage and
grade by qualified gynaecological oncologists, CAl25 mea_
surement befbre surgery, age, self-reported menopausal sta_
tus, pre-existing conditions or medications and auy prior
history of malignancy were obtained from patient medical
records (first deidentified to maintain patient anonymity).
Patient details immediately relevant to this study are pro_
vided in 'l'able I. Measurement of serum CAl25 and total
urine creatinine was performed in the diagnostic pathology
laboratory at the Monash Medical Centre, Melbourne, Aus-
tralia. Ethical approval was obtained from the SouthernHealth Human Research .Ethics Committee (HREC
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Table 1. Summary of patient samples used for mRNA and protein expression studies
Group Pathology Stage
Antagonistic CXCLl0 in ovarian tumours
Median
Ase (lQR)
Median
cA125 0QR)
Menopausal
status
Control (n = l2)
Borderline /
low grade (n = 14)
tarly (n = 5)
Late (n = 28)
Serous cystadenoma (n = 4) nla nla
Serous cystadenofi broma (n : 2)
Non-ovarian benign (n 
- 6)
Serous borderline (n: 10) nla nla
Serous carcinoma (n : a) 1 lc
Serous adenocarcinoma 3 lb-c
Serous adenocarcinoma 3 lllb-c
53 146-64)
4,7 (42, 70\
s6 154-57)
65 \57 ,7 5)
67 (55,101)
^/ 11? . ^.\>o \to, !t))
771 (48.289)
7 40 1397 ,2500)
Post
Mixed
Post
Post
certificates #06032C, #020318), with all participants provid-
ing prior informed written conserrt.
CXCtl0 immunoassay in plasma and urine
Immunoassays were performed using a custom Milliplex'IM
cytokine assay (MilliPlex MAP Human Cytokine; Millipore,
Melbourne, VIC, Australia), as directed by the manufacturer.
Individual matched samples of urine and plasma from each
patient were assayed in duplicate. Before assay, plasma samples
were diluted l:60 with assay buffer; urine was similarly diluted
l:5. In brief, standards and samples were incubated in the pres,
ence of antibody-coupled beads overnight (16-18 hr) at 4"C
with mild agitation. Incubation with detection antibodies was
performed for I hr at room temperature (RT) with mild agita-
tion. Fluorescent intensity measurements were acquired using a
Bioplex2O0 instrument, and concentrations were determined
using BioManager analysis software (BioRad, Hercules CA).
Urine concentrations of CXCL1O were further normalised
against total urine creatinine lbr each patie'nt. The minimum
detectible CXCLI0 concentration, as determined by the manu-
facturer, was 2.2 pg/ml (mean minimum detectible concen-
tration + 2 standard deviations). Intra-assay variation, as
assessed by ToCV in median fluorescent intensity across dupli-
cate measurements and standards, was routinely less than 5%.
RNA extraction and anatysis by real-time RT-PCR
Total RNA was isolated liom tumour lysates r.rsing an
RNeasy Mini kit (Qiagen, Melbourne Australia) according to
the manufacturer's instructions. RNA quality was assessed by
gel electrophoresis and UV absorbance 2601280 ratios
(acceptable range 1.8-2.0). A total of 300 ng RNA was
reverse transcribed using SuperScript III (Invitrogen, Mel-
bourne Australia). Quantitative RT-PCR was performed using
an ABI 7900HT Fast Real-Time PCR Sysrem (Applied Bio-
systems, Melbourne Australia) with primers for CXCLIO
(primer ID: Hs0l12425l_gl) and lruman 1BS Ribosomal
RNA (primer ID: Hs03928985_gl). PCR was carried out as
follows: 50'C for 2 min and 95'C for l0 min, followed by 40
cycles of amplification at 95"C for 15 sec and annealing at
60"C for I min. The rRNA probe was labelled with VIC']'M
dye and the probe for CXCLI0 was labelled with 6-carbory-
Iluorescein (FAM). All qPCR was carried out in triplicate.
I)ata values were extracted with the SDS v2.0 software tool
(Applied Biosysterns), and expression levels were determined
using the AACI (Cycle Threshold) method,rs with l8S ribo-
somal RNA as the calibrator.
Preparation of tissue lysates for SDS-PAGE
'I'issues used for SDS-PAGE and Western blotting experi-
ments were treated as follows. A 50 mg portion of snap-
frozen tumour tissue was washed three times in ice-cold 20
mM 'fris (pH 7.4 to remove any visible blood. Each tissue
was then homogenised in 400 ml lysis buff'er (7 M vea,20
mM Tris, 2 mM MgCl2, pH 9.0 with HCI) containing 2x
EDTA-free protease inhibitor cocktail (Roche, Castle Hill,
Australia) and 500 U/ml of benzonase endonuclease (Signra,
Sydney Australia). The homogenate was incubated for 15
min on ice and then diluted with 400 nrl of 1 M triethylam-
nronium bicarbonate (TEAB) (Sigma). The solution was vor-
texed and incubated for a further 15 min on ice, and
insoluble material was pelletted by centrifugation at 21,0009
for l0 min at 4'C (Eppendorf 5415 rotor). The pellet was
rehomogenised in a further 100 nrl of I M TEAB, and after
incubation and centrifugation as above the supernatants were
pooled. Samples were then reduced with 5 mM Tris(2-car-
boryethyl)phosphine (Sigma) for I hr at 60"C and alkylated
using 18 mM iodoacetamide (Sigma) for 30 min in the dark.
Proteins were then precipitated in 2 vol of acetone as previ-
ously described.re 'I'he precipitated proteins were resuspended
in a small volume of urea buffer (7 M urea, 2 M thiourea
and l%o CTBZO wt/vol) and assayed according to the method
of liradford. All samples were adjusted to l0 mg/rnl in urea
buffer, snap-frozen and stored at 
-80oC before use.
SDS-PAGE and Western btotting
Duplicate protein aliquots for each sample lvere diluted to
20 ml in 2X LDS sample buffer (Invitrogen, Carlsbad, CA).
SDS-PAGE was carried out in a 4-20o/o crtterion polyacryl-
amide gel (BioRad) at 250 V for 30 min. To avoid any poten-
tial fbr bias during analysis, each sample was assigned a
random number from I to 1,000 before separation and
lnt. I. Cancer: lr4, 530*547 (2014) @ 2013 UtCC
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loaded in order of random number without
of sample identity.
any knowledge Table 2. Summary of tissue microarray parameters
Variable Number
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Separated proteins were transferred to PVDF membrane
using a TransBlot Turbo semidry transfer device (BioRad).
Membranes were dried at 37"C for I hr. After rewetting in
l00o/o methanol, membranes were blocked for 45 min in 5%
skim milk porvder * 0.2% Tween 20 in PBS, and incubated
overnight in Tween 20/PBS at 4'C with prinary chicken
antisera against CXCl.l0 (diluted l:2,500, AbCam
#ab117319) or rabbit antisera against p-actin (diluted
l:100,000, Abcam #ab8227). Recombinant CXCL1O (Abcam
#ab98l0) was used as a control. Seconclary antibody was goat
anti-rabbit IgG (diluted l:100,000, Abcam #ab97051) or rab-
bit anti-chicken IgG (diluted l:50,000, Abcam #ab97140)
conjugated to horseradish peroxidise. Immunostaining was
detected using Clarityrt ECL Western Substrate (BioRad)
and imaged using a ChemidocMP (BioRad). Quantitative
image analysis was performed using Imagelab 4.1 software
(build 16, 2012) using the default settings, and the ratio of
CXCLI0:B-actin was calculated for every sample (blinded to
their identities). Samples were then reidentified and grouped
for subsequent statistical analysis.
lmmunohistochemistry
Inmmunohistochemical staining of formalin-fixed paraf;fin sec-
tions was carried out using commercially available tissue micro-
array slides (US Biomax, Rockville, MD). Arrays contained
duplicate l-mm diameter cores (5-mm thickness) from benign
(a : 30) or malignant (n:9a) ovarian tumours, normal
cancer-adjacent (n : 5) or histologically normal (n : 5) tissues
(see Table 2 and Supporting Information Table Sl). Slides were
deparaffinised in Histolene (Sigma) and descending grades of
ethanol before antig-en retrieval. Antigen retrieval was per-
formed as described2o using 50 mM glycine, pH 3.5. Slides were
blocked in l0% goat serum, l0% CAS block (Invitrogen) in 5%
bovine serum albumin/Tris-buffered saline before overnight
incubation with primary antibody against CXCLI0 (Abcam
ab9807, diluted l:50), CD45 (Epitomics t69l-1, diluted l:500),
CD3 (Dako, Campbellfield Australia MTZS4, diluted 1:50) or
DPP4 (Abcam abl14033, diluted l:800). Secondary antibody
was biotinylated goat anti-rabbit (Vector Laboratories, Burlin,
game CA) or anti-mouse (Dako E0433) as appropriate. Slides
were incubated with secondary antibody (diluted l:200) tbr 30
min, followed by the Vectastain Elite ABC kit according to the
nranufacturer's instructions (Vector Laboratories). Antibody
binding was detected as a brown precipitate after clevelopnrent
with 3,3'-diaminobenzidine tetrahydrochloride (DakoCytorna-
tion) and counterstained using I\{ayer's haematorylin (Sigma).
Negative controls were performed for all slides using secondary
antibody alone, and an immunising CXCl.l0 peptide used at
between 2- and l0-fold excess was employed in blocking expen-
ments (see Supporting Information S2). Slides were dehydrated
through ascending grades of ethanol and histolene, and
mounted with coverslips using dibutyl phthalate xylene (DEpX,
BDH; Merck, Melbourne Australia). Slides were imaged using
lnt. J. Cancer: 734, 530-S4t (2014) O 2013 U|CC
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Ungraded or mixed 73 10
Full detaits may be found in Supporting Information 51 and 52.
an Aperio ScanScope CS and XT system (Aperio Technologies,
Vista CA) at 20X magnification. Representative tumour mar-
gins rvere marked by a qualified pathologist, and serial sections
were analysed for staining intensity using Aperio ImageScope
(version 1 1.2.0.780). Staining intensity was scored by the soft-
ware on a scale of 0 to +3.
lmmunoprecipitation of CXCL10 from tissue lysates
Anti-CXCLl0 antibodies (ab9S07) were conjugated to protein
A/G agarose at a concentration of l0 mg per 50 ml ofprotein
A/G slurry, using a Pierce Crosslink Ip kit (Thermo Scien-
tific, Rockford, IL) as described by the manufacturer. A 20-
mg protein aliquot from each tumour lysate was pooled to
form four groups (benign, low-grade, high-grade early stage
or high-grade late stage). A total of 50 rng protein frorn each
sample pool was diluted 1:10 with lysis/wash buffer (25 mM
Tris, l-50 mM NaCI, I mM EDTA, I%o Np-40 and,50,6 $yc_
erol, pH 7.4) and precleare'd for 2 hr at room temp by incu-
bation with protein A/G slurry. 'I'he supematant was then
harvested and incubated with antibody-conjugated beatls
overnight at 4oC. Captured antigens were eluted in 0.1 M
glycine (pH 2.6) and adjusted to I M urea, 100 mM Tris (pH
8.5). A 1/5 aliquot of each sample was assessed by Western
Total # patients
Age
Median
rq range
FIGO stage
I
ll
ill
Unstagerl
Histological Subtype
Serous
Mucinous
Endometroid
Clear cell
benrgn
NormaI
No rm a l-tum o u r- a d jacce nt
Grade
1
2
735
47
39-55
4b
17
6
1
o/
11
11
4
5V
5
5
73
37
34
20
4
I
50
8
I
3
22
4
4
4
10
27
534
blotting, whereas the remaining sample was digested with
100 ng of recombinant endoproteinase GluC (Promega, Mad-
ison, WI) at 25'C overnight. Peptides were desalted using
Cl8 TopTips (Glygen, Columbia, MD), dried in a vacuurn
centrifuge and resuspended in 0.057o heptafluorobutyric acid
(Thermo Fisher Scientific, Melbourne, Australia) for analysis
by LC-MS/MS.
rc-Ms/Ms
Desalted peptides were injected into a Dionex Ultimate'r'M
3000 RSLCnano system (Dionex, Sunnyvale, CA) and loaded
onto a PepSwift Monolithic Trap Column (200 mm i.d X 5
nrnr) (Dionex) at a flow rate of 10 ml/min. After 7 rnin the
trap column was switched in line with a Pepswift Monoiithic
Capillary Column (200 mm i.d x 5cm) (Dionex) at a flow
rate of 1.5 ml/nrin using mobile phase A (0.05% heptafluoro-
butynoic acid in water). Separation was perfcrrmed in a linear
4-70o/o gradient of mobile phase B (50o/o H2Ol50Vo acetoni-
trilel0.I{o/o trifluoroacetic acid, vol/vol). Peptides were coe,
luted with HCCA matrix (Bruker Daltonics, Melbourne,
Australia) solution at a flow rate of 2 nrl/min and spotted
directly to 384 spot 800 mm AnchorChip MALDI target
plates (Bruker Daltonics), using Protei_neer FC II robotic frac-
tion collector (Bruker Daltonics) and allowed to dry.
Mass spectm were acquired using an tlltraflextreme
MALDI-TOF (Bruker Daltonics). WARP-I-C 1,2 software
(Bruker Daltonics) was used to automate the acquisition of par-
ent ions and selection of up to 20 peptides per target spot for
subsequent MS/MS analysis. Extemal calibration was performed
automatically on Peptide Calibration Standard II (Bruker Dal-
tonics) spotted onto Anchorchip calibration spots. Spectra rvere
automatically processed in FlexAnalysis 3.3 (Bruker Daltonics).
Further processing and identification were performed using
ProteinScape 2.1 (Bruker Daltonics). Proteins were searched
against the SwissProt database (May16 2012; 536,029 entries)
using an in-house version of MASCOT 2.3.01 (Matrix Science,
London, UK) with the following parameter settings: no_enzyme
(for CXCLlO N-terrninal daection) or Glu-C, I missed cleav-
age, Homo sapiens 
^s 
organisrn, carbamidomethylation (C) as a
6xed modification, oxidation as a variable rnodification, 80
ppm MS tolerance, 1.5 Da MS/MS tolerance, minimum Mascot
protein score > 30 and peptide score > 20. All MS/MS data of
CXCLI0 peptides and modifications were then also manually
evaluated using Biotools 3.2 (Bruker Daltonics).
MALDI imaging mass spectrometry
Fresh-frozen tissue sections (12-mm thick) were prepared on
indium-tin oxide-coated slides, fixed in 100% ethanol and over-
layed with sinnapinic acid matrix solution (10 g/l in 60% acetoni-
trile and 0.27o trifluoroacetic acid) using a Bruker Inrageprep
device (Bruker Daltonics) as recommended by the manufacturer.
MALDI images were acquired in the mass/charge range 2,000-
20,000 using a Bruker Llltraflex III TOFiTOF (Bruker Daltonics)
in linear positive ion mode, with a sampling rate of 0.1 GS/sec.
Acquisition was performed using a Smartbeam laser with a repeti-
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tion rate of200 Hz. A spatial resolution of 100 mm was used and
each MS spectrum was obtained by accumulation of 400 consecu-
tive laser shots. Images were reconstructed using Fleximaging v2.l
(Bruker Daltonics) and normalised using a Y,,"u./Y,,"* threshold
of 0.5. External calibration was performed using a Protein Calibra-
tion Standard (Bruker Daltonics) spotted on one comer of each
sample. After image acquisition the matrix was removed from
each slide by washing twice in 100%o methanol, followed by incu-
bation in 100% acetone for 5 min at RT. Tissue sections were then
aA dried before H&E staining (as above). H&E-stained sections
were scanned at 1,500 dpi resolution and coregistered with their
respective ion images. All image analysis was carried out using
ClinProTools v2.2 (Bruker Daltonics).
StatisticaI analysis
Statistical analyses were performed using GraphPad Prism
(GraphPad Software, La Jolla CA). Immunoassay measure-
ments that returned values below the minimum detectable
concentration (MDC) were assigned a value corresponding to
half the MDC + 2 SD, Missing values were assigned rhe
median for the particular sample group. All data (immunoas-
say, protein expression and immunohistochemical staining)
were log transformed to approximate normality, and signifi-
cance was determined using one-way ANOVA and Bonfer-
roni posl hoc test. Pairwise compali56ps were performed
using Student's t-test; where variances were significantly dif-
ferent between groups, Welch's correction was applied.
Results of p < 0.01 were considered significant.
Results
CXCLlO is overexpressed in serous ovarian tumours
Tumour-specific CXCL1O expression rvas assessed by qRT-
PCR in a small cohort of patients, matched for age, disease
pathology and menopausal status (Table l). mRNA encoding
CXCLI0 was significantly higher in both early- and late-stage
tumours, relative to a control group comprised of patients
with either serous benign ovarian tumours (n :6) or other
nonovarian, benign gynaecological disease (n:6) (Fig. la).
Expression was highest in patients with early-stage
[Fhdhiation Internationale de Gynhbologie et d'Obstietrique
(FICO) stage Ib-cl tumours, with a significant decrease evi-
dent in late-stage (FIGO stage IIIc) turnours. Protein expres-
sion was then examined in an expanded cohort, comprising
additional patients with late-stage tumours as well as a group
of borderline/low-grade (Grade l) tumours (Table l).
CXCLI0 was detected in all samples at an apparent molecu-
lar mass of 
-10 kl)a (representative Western blot shown in
Fig. lb). Quantitative analysis of the ratio of total CXCLI0:
B-actin revealed a significant increase in CXCLI0 protein
abundance in all high-grade tumour samples relative to con-
trols and also (for early-stage tumours) to samples from bor-
derline/low-grade malignancies (Fig. lc). Some degradation of
B-actin was observed; however, this was an artefact of the
high protein load (SO mg per lane) necessary to reliably visu-
alise CXCLI0. Highest CXCLIO expression was observed in
lnt. J. Cancer: 7t4, 530-547 (2014) O 2013 U|CC
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control early late
Benign
patients with early-stage disease, consistent with the elevated
mRNA expression observed.
We also evaluated the presence of CXCLIo in urine and
plasma samples from the same group of paticnts. Despite the
tumour'specific production of CXCLIo observed, there was no
signifrcaot increase in secreted levels in either plasnra or urine
(Supporting Information Fig. Sr). Indeed, a small but signifi-
cant decrease was identified in patieits with early-stage, high-
grade disease, as has previously been reported.rT The data sug,
gest that despite overexpressiot'l of CXCLI0 in high-grade
ovaian tumou6, total circulating/secreted levels of CXCLI0
remain relatively unchanged throughout disease progression.
Tlssue erpresslon of CXCL1o suppons the exlstence of the
'imnunoreactive" serous epitheliat tunout subtype
Imnrunohistochernical staining for CXCLIo was performed on
tissue micloarray slides comprising duplicate tissue cores from(i) histologicaly normal, (ii) normal cancer-adiacent, (iii)
benign or (ir) epithelial tumour tissue sections (see Supporting
Information Sl and S2). CXCLI0 stainirg was low in histolog-
ically normal, normal-cancer-ad.iacent (NCA'I ) and benign
Int. ,. Cancer: 114, 530-541 (2014) O 2013 UtCC
ri8!re 1. cxcll0 expression in tumour tissues. mRNA and protein were extracted from multiple tissue samples and the exoression levets ofCxct10 detemined (a) qPcR analysis of cXcL10 mRNA expression in a restricted cohort of patients (defined in Table l). 6) Tumour lissue
lysates were deidentified. randotnised and CXCLIo plotein abundance analysed by Western blotting. A repregentative image is shown. (O Sig-
nal antensity corresponding to CXcLlo was nomalised against B-actin (average of tlvo independent replicates per sample)- After this carcu6-
tton samples w€re rcidentified for grouping and subsequent statistical analysis. sample groups and pathology are indicated. 'p< 0.05i
"p < 0.01.
Late
stroma.l tissues (Fig. 2a, panel ii representative images shown
in Figs. 3.r-3c). Intense CXCLIo staining was observed specifi,
cally in association with benign cystic epithelium (Fig 2d).
CXCLIo was present in malignant epithelial tissues in all
tumour ty.pes (Figs. 3d and 3e and Supporting Information
Fig. S2A). Notably, two distincr patterns of CXCLIo reactMty
were evident in serous tumou$ (Fig.2a). l,ow-level CXCLI0
expression was observed in 
-60% of serous tumours, similar
to benign and histologically normal ovary (see Fig. 2d and
Supporting Information S2). By contrast, 
-40% of tumours
expressed significandy elerated levels of CXCLI0 (Fig 2a),
Total CXCLlo expression in serous tunours was elevated
(P< 0.01) compared to normal, NCAT and benign groups
(Fig. 2c); other epithelial tumour tlpes showed no significant
increase (Fig. 2d), although this may be an anefact of the
small numben examined. The bimodal expression observed in
serous tumours was independeot of age, stage or tumour
grade, suggesting the presence of two different molecular path-
ological subt'?es and consistent with the lecently described
"immunoreactive" subset of xrous oladan tumours that
express elerated levels of CXCLIO mRNA.'zr
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Figure 2. Quantitative analysis of immunohistochemical staining for CXCL10, CD45 and CD3. Tissue microarray slides were stained for
CXCL10, CD45 and CD3, representative areas of tumour marked and positive staining scored on an intensity scale of 0 to +3. The o/o posi-
tive cetts (total of +2 and +3 scoring cetls \rersus total cell count) were plotted according to sample type. Each circle represents the aver-
age o/o positive cells from duplicate tissue sections per patient. Error bars represent mean a SEM. (a) o/o positive celts. Dotted lines
represent the mean + SD for normal tissues. Grey bars on the righlhand side indlcate the two populations of serous tumours based on
expression levels. (b) Linear regression analysis for CD45 and CD3 vs. CXCL1o. Significant correlation coefficients are indicated. (c) Recruit-
ment index for CD45 and CD3 positive cells as a function of CXCLl0 expression. Dashed lines represent the mean + 5D for histologicalty
normal tissue. Rls are divided into "low," "normal" and "high" accordingly. Groups are as foilows: normal-histologically normal tissue;
NCAT-normal cancer-adjacent tissue; benign-benign tumour; EPI-benign-benign tumour epitheliat cell layer; matignant-serous epithelial
tumour. t*p< 0.01; *."p < 0.001.
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Figure 3. lmmunohistochemical staining of tumour tissue sections for CXCL10 and CD45. Representative tissue sections stained for either
CXCL1o, CD45 or CD3 are shown. Scale bars are indicated; each 50-mm section is an enlargement of the adiacent 200'mm section. Positive
staining appears brown against blue H&E staining. Black arrows indicate isotated CD4s"positive cetls. Sample types are histologically nor'
maI ovirian tissue (a, f, l0; normal cancer.adjacent ovarian tissue (b, g, l); benign ovarian tissue (C h, m; and serous ovarian tumour tissue
.type A. (d, i, n) and "type B" (e, j, o). Fult TMA slides are provided in Supporting Information 51 and 52. [Color figure can be viewed in
the ontine issue, which is available at witeyonlinetibrary.com.l
CXCI1O expression does not correlate with teucocyte
infiltration in serous epithelial tumours
To evaluate T-cell recruitment in resPonse to elevated
CXCI,10, serial tumour sections were examined for expres-
sion of the general leucocyte nrarker Cl)4522 and the T-cell
marker CD3. CD45-expressing cells lvere Present in low
numbers in both normal and cancer-adjacent tissues (Fig.
2a, panel ii; representative images shown in Figs. 3/ and
3g), whereas in benign tissues CD45+ cells were present in
elevated numbers particularly at the benign epithelium
(Figs. 2a and 3h). By contrast, CD45* cells in serous
tumours were signilicantly fewer (P < O.OOI) than in benign
tissues, and were not significantly different to histologically
normal tissue (Figs. 2a and 3i and 3l). There was a signifi-
cant positive correlation between CXCLI0 and CD45
expression in benign tissues (Fig. 2b, panel i), indicative of
the positive influence of CXCL1O expression on leucocyte
recruitment. However, in malignant tumour sections there
Int. J. Cancer: 1t4,530-547 (2014) o 2013 ulcc
was no apparent correlation between CXCLIO expression
and CD45 staining (Fig. 2b).
Immunostaining for CD3 was used to demonstrate the
presence of T-cells in serial sections. CD3* T-cells were Pres-
ent in low numbers in normal, NCAT and benign stromal
tissue, whereas they were significantly elevated in benign epi-
thelium, consistent with CXCLI0 and CD45 staining (Figs.
2a, panel iii and 3k-32). In direct contrast to CXCL1O
abundance, CD3 * cells were not significantly elevated in any
tumour type (Figs. 2a, panel iii and 3n ar'd 3o). Linear
regression analysis demonstrated a significant positive corre-
lation between CXCl.l0 and CD3 expression in benign tis-
sues, similar to that observed for CD45; no significant
correlation was observed between CD3 and CXCLI0 in
malignant tissues (Fig. 2&, panel ii).
To further clarifi the relationship between CXCL1O and
tumour-infiltrating leucocytes, we assessed the ratio of
CXCLI0:CD45 and CXCL10:CD3 positive cells (recruitment
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Figure 5. lmaging mass spectrometry of tumour tissue sections for the presence of intact and cteaved CXCL10. (a) Averaged mass spectra for
patient tissue sections fiom benign, borderline/low-grade, high-grade early-stage and high-grade late-stage tumours. An mlzof 8657.8 o(
8451.6 conesponds to the methionine-oxidised form of intact or cleaved CXCL10, respectively. Patient numbers and gToups are indicated. (b)
Representative IMS images demonstrating the localisation of intact and cteaved CXCL10 in tumour tissue sections for hvo individual patients.
Panels are (D H&E-stained tissue; (ii) intact CXCL10 (m128657.8):0ii) cleaved CXCLl0 (m/28451.6) and 0v) overlay of panels 0i) and 0ii). Scale
is indicated. On-tissue peptide digestion and MS/MS anatysis confirming the identity of CXCL1O is provided in Supporting Information 55. lCotor
figure can be viewed in the online issue, which is available at wileyonlinetibrary.com.l
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with an mlz of 2687.4 was also observed specifically in turnour
samplet this variant was undetectable in benign tissue lysate
(Fig. ab) or in a sample of recombinant CXCLlO (see Supporting
Information 53 and S4). De novo sequence analysis of this pep-
tide identified the amino acid sequence NHr-LSRTVRCTCI-
SISNQPVNPRSLE- (Fig. 4c, lower panel), corresponding to the
same CXCLIO peptide but with the N-terminal Val-Pro dipep'
tide removed. Importantly, the ratio of intact:cleaved peptide was
clearly different in each sample (Fig. 4&) suggesting their dift'er-
ential presence in tumour tissue.
Serial sections were also examined for the presence of
DPPase 4 (DPP4), an enzyme known to cleave the N-terminus
of CXCLI0 both in vitro and vilo.rr Elevated DPP4 expression
was observed in serous and endometroid tumours, whereas
benign tissue showed significant decrease in DPP4 expression
relative to normal (Supporting Information S2B). Interestingly,
DPP4 was also elevated in normal cancer-adjacent tissues.
DPP4 and CXCLIO displayed a linear correlation in both benign
and malignant tissues, with significantly lower DPP4 expression
lnt. f. Cancer: 1t4, 53o-54r (2014) @ 2013 UICC
in benign disease (Supporting Information S2B). The data dem-
onstrate that both N-terminally processed CXCLIO-a variant
known to directly antagonise leucocyte recruitment-and the
enzyme DPP4 are present in serous epithelial ovarian tumours.
Antagonistic CXCL1O is localised to the tumour ePithetium
'fhere are currently no commercially available antibodies suita-
ble for immunohistochemical studies that can discriminate
between intact and cleaved CXCLI0 in tissue sections. There-
fore, we applied MALDI imaging mass spectrometry (IMS) to
examine the localisation of cleaved CXCLI0 in tumour sections
from individual patients with either benigr or malignant dis-
ease. Masses corresponding to both the intact (mlz 8657.8) and
cleaved \mlz 8461.6) forms of CXCL1O (accounting for oxida-
tion of methionine) were observed in all malignant tissues; in
benign tissues, the mass corresponding to cleaved CXCLI0 was
undetectable (Fig. 5a). Cleaved CXCLI0 was abundant in high-
grade turnour tissues and was localised to the tumour epithe-
lium (Fig. 5&), consistent with the distribution observed by
(l) H&E staln (lll Intact (iil) cleaved
amm
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b
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immunohistochemical staining. The identity of CXCLI0 in IMS
was confirmed by subsequent on-tissue digestion and MS/MS
identification of several peptides belonging to CXCLIO (see Sup-
porting Information S5A). The presence of cleaved CXCLI0 in
these seclions also correlated with increased CXCLIO and
decreased CD45+ cells infiltrate (see Supporting Information
S5B). Together, the data strongly support the hypothesis that
protmlytic cleavage of CXCLI0 occurs in the turuour epithe-
lium, where it can act to inhibit leucocyte recruitment.
Dlscussion
Our study provides the first evidence for the presence of
N-terminally cleaved CXCLI0 (denoted CXCL1013_77;) in epi-
thelial ovarian tumours and its antagonism of tumour-
specifc leucocyte recruitment. Inhibition of T-cell recruit-
ment by CXCLl013-zz1 was recently established as a prognos-
tically important factor in the pathology of liver diseaserr;
our data suggest that a similar mechanism may also operate
in a subset of epithelial ovarian tumours, leading to impair-
ment of the immune response and ultimately influencing
prognosis. Ironically, we identified this rnechanism in ovarian
tumours overexpressing CXCLI0, which were previously
termed "immunoreactive"2r; the presence of N-terminally
cleaved CXCLI0 in tumours suggests that its role may, in
fact, be partially immur-rosuppressive. The presence of antago-
nistic CXCLI0 in these tumours was not ubiquitous, and rep-
resents an additional molecular classifier rather than an
absolute. Nevertheless, the hitherto unreported nature of this
modification in at least some ovarian tumours is an impor-
tant biological feature that could partially explain the low leu-
cocyte recruitment observed here and in other studies,s'r3
and provides a potential new avenue for their treatment.
Chronic inflammation underlies the development, growth
and progression of many types of solid tumoursT; therefore, it
is of paramount importance to identifu the molecules involved
and their protumour or antitumour activities that may influ-
ence tumour growth and metastasis. Our mRNA and protein
expression data support the recent identification of the
"immunoreactive," CXCllO-overexpressing tumour group,2r
and additionally extend this definition to include patients with
high-grade, early-stage (FIGO stage I) disease-representing a
subset that was not included in the larger scale analyses
reported. Interestingly, we noted higher expression in patients
with Stage I disease compared to those diagnosed with nrore
advanced tumours. Decreased CXCLI0 expression correlated
with increasing stage of cancer has also been reported for both
endometrial and cervical cancers,'3'2' in association with the
loss of b-FGF- and/or VEGF-supported induction of CXCLI0
expression. Our data suggest that an inverse relationship
between CXCLIO expression and disease stage might also
occur in serous ovarian tumours, and that CXCLI0 expression
may be attenuated during disease progression.
Post-translational enzymatic processing regulates the func-
tion of a number of chemokines (reviewed in Ref. 25). CXCLIO
is an established in yilro substrate for a number of
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enzymes,"'26-30 in particular the DPPases DPP4 and DPP8
(and probably DPP9) that catalyse cleavage of the Val-Pro
dipeptide from its N-terminus.r0-r2'rr Recent work established
that DPP4-mediated cleavage was responsible for failed leuco-
ryte recruitment in liverrl; there has previously been no direct
evidence for similar cleavage of CXCL1O in tumours. DPP4 is
overexpressed in ovarian tumour tissuelo and cell lines, and
has been associated with changes in proliferation, adhesion
and migration as well as enhanced sensitivity to paclitaxel.32-34
It is also associated with decreased MMP2 activity and
increased ievels of tissue inhibitors of matrix metalloprotei-
nases." Our data show a significant correlation between DPP4,
CXCLI0 and reduced ieucocyte infiltration in ovarian tumours,
suggesting that tumour-expressed DPP4 may be a contributor
to the production of antagonistic CXCLIO. However, the data
do not exclude the possibility that DPP8 and/or DPPS may
also contribute; whilst DPPS and DPPg are intracellular
enzymes, their activities have also been identified external to
cells,3s presumably as a result of tissue necrosis. Although both
DPPS and DPPg are expressed in ovarian cancer cell lines,36
theil presence in tumour tissue remains to be determined.
Both the presence and type of infiltrating TJeucocytes pres-
ent in ovarian tumours are directly correlated with patient
prognosis.s'r3'37'38 (IXCLl0 normally functions as a potent che-
moattractant, recruiting activated CXCR3' T-cells into sites of
inflammationT; the CXCL101:-zz;, however, acts in a dominant
negative rnanner to bind CXCR3 and prevent signalling or che-
motaxis.tr't2'rl By contrast to serous benign epithelial tumours,
we observed few tumour-infiltrating CD3* leucocytes (TILs)
in malignant tissue despite high CXCLlO expression. Previous
reports have also noted lodabsent 'l"ILs in both ovanan
tumour sectionss'!3 and a mouse xenograft model.3e These
findings can now be partially explained by the abundance of
antagonistic CXCLl013_zz1 in these sarnples. Ilenign tumour
samples, in which only the intact, chemoattractive CXCLI0
was present, were able to recruit T-cells; rnalignant tumours, in
which varied levels of QXCLl0l:-zz1 were identified, showed
substantially less T-cell recruitrnent. Recent work has suggested
that increased numbers of T,"r. infiltrate tumours with advanc-
ing stage, despite an early ThlT response.u Therefore, an
increased abundance of antagonistic CXCll0l3_zzl in these
tumours rnight promote early impairnrent of activated T-cell
recruitment, increasing the eft'ective ratio of infiltration by T."r"
and ultimately leading to poor prognosis. Therefore, the ratio
of intact:cleaved CXCLI0 in tumour tissue likely represents an
important prognostic feature of the "immunoreactive" subset
of serous epithelial ovarian tumours.
Interestingiy, there is a long-standing link between type II dia-
betes (T2D) and prognosis for ovarian cancer patients.*' DPP4
activity has a well-established role in the development of T'2D,ar
and DPP4-specific inhibitors have become an effective therapy for
diabetes managenlent. Although our data do not unambiguously
demonstrate which DPPase cleaves CXCL1O i-n ovarian tumours,
it is possible that DPP4 inhibitors may find clinical applicarion in
the treatment of patients with ovarian cancers. Indeed, studies
lnt. l. Cancer: 1t4, 530-54r (2014) O 2013 UICC
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have suggested that patients prescribed antidiabetes medications
have lower risk of hepatocellular carcinoma,a2 and very recently
sitagliptin (a DPP4 inhibitor used in the management of T2D)
was found to reduce colon cancer in rats.a3 Therefore, the identifi-
cation of antagonistic CXCLl0lr-zz; in epithelial ovarian tumours
may repres€nt an important new avenue for targeted therapeutic
strategies using existing medications. It is now important to estab-
lish which enzynre/s are responsible for CXCLI0 pror:essing, the
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